Citations

Clear

3138 citation(s) found for "Smith, AM".

Chemokines in ICU Delirium: An Exploratory Study
Smith, Ryan J. , Cartin‐Ceba, Rodrigo , Lachner, Christian , Trivedi, Shubham , Khatua, Biswajit , Rabinstein, Alejandro A. , Singh, Vijay , Gajic, Ognjen

Mayo Clinic

Critical Care Explorations | July 5, 2022 | Volume: 4 | Issue: 7 | Pages: e0729

10.1097/cce.0000000000000729 | PMID 35815182 Get It

OBJECTIVES: The pathophysiology of delirium is complex and incompletely understood. Inflammation is hypothesized to be integral to its development due to effects on blood brain barrier integrity, facilitation of leukocyte extravasation into brain parenchyma, and propagation of neuroinflammation. Septic shock is the prototypical condition associated with ICU delirium; however, the relative contribution of resultant hypotension and systemic inflammation to the development of delirium is unknown. DESIGN: This was a prospective exploratory study. SETTING: A multidisciplinary ICU at an academic medical center in Phoenix, AZ. PATIENTS: Critically ill patients older than or equal to 18 years old admitted to the ICU. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: Screening for delirium was performed using the Confusion Assessment Method for the ICU tool. The levels of C-C motif ligand 2 (CCL2), C-C motif ligand 3, C-X-C motif chemokine ligand 1, C-X-C motif chemokine ligand 10, and interleukin-8 were measured in serum samples obtained within 12 hours of ICU admission. Univariate and multivariate analyses were performed to assess the association of delirium with patient data pertaining to hospital course, laboratory values, vital signs, medication administration, and levels of the aforementioned chemokines. Forty-one of 119 patients (34.5%) in the study cohort developed ICU delirium. Each chemokine studied was associated with delirium on univariate analyses; however, CCL2 was the only chemokine found to be independently associated with the development of delirium on multivariable analysis. The association of increased CCL2 levels with delirium remained robust in various models controlling for age, presence of shock, Sequential Organ Failure Assessment score, Acute Physiology and Chronic Health Evaluation IV score, mean arterial pressure at presentation, lowest mean arterial pressure, and total opioid, midazolam, propofol, and dexmedetomidine exposure. CONCLUSIONS: The demonstrated relationship between CCL2 and delirium suggests this chemokine may play a role in the development of delirium and warrants further investigation.
Primary Fixation and Cyclic Performance of Single-Stitch All-Inside and Inside-Out Meniscal Devices for Repairing Vertical Longitudinal Meniscal Tears
Bachmaier, Samuel , Krych, Aaron J. , Smith, Patrick A. , Herbort, Mirco , Ritter, Daniel, LaPrade, Robert F. , Krych, Aaron J , LaPrade, Robert F , Wijdicks, Coen A.

Mayo Clinic

The American Journal of Sports Medicine | July 5, 2022 | Volume: 50 | Issue: 10 | Pages: 2705-2713

10.1177/03635465221107086 | PMID 35787211 Get It

Background: Primary device fixation and the resistance against gap formation during repetitive loading influence the quality of meniscal repair. There are limited biomechanical data comparing primary tensioning and cyclic behavior of all-inside versus inside-out repair. Hypothesis: All-inside devices provide higher initial load on the meniscal repair than inside-out fixation, and stiffer constructs show higher resistance against gap formation during cyclic loading. Study Design: Controlled laboratory study. Methods: In total, 60 longitudinal bucket-handle tears in human cadaveric menisci were created and repaired with a single stitch and randomly assigned to 4 all-inside groups (TrueSpan, FastFix 360, Stryker AIR, FiberStich) and 2 inside-out groups (suture repair [IO-S], suture tape [IO-ST]). Residual load after repair tensioning (50 N) and relief displacement were measured. Constructs underwent cyclic loading between 2 and 20 N over 500 cycles (0.75 Hz) with cyclic stiffness, gap formation, and final peak elongation measured. Ultimate load and stiffness were analyzed during pull to failure (3.15 mm/s). Results: All-inside repair demonstrated significantly higher primary fixation strength than inside-out repair. The significantly highest load (mean ± SD; 20.1 ± 0.9 N; P < .037) and relief displacement (–2.40 ± 0.32 mm; P < .03) were for the knotless soft anchoring FiberStich group. The lowest initial load (9.0 ± 1.5 N; P < .001) and relief displacement (–1.39 ± 0.26 mm; P < .045) were for the IO-S repair group. The final gap formation (500th cycle) of FiberStich (0.75 ± 0.37 mm; P < .02) was significantly smaller than others and that of the IO-S (1.47 ± 0.33 mm; P < .045) significantly larger. The construct stiffness of the FiberStich and IO-ST groups was significantly greater at the end of cyclic testing (16.7 ± 0.80 and 15.5 ± 1.42 N/mm; P < .042, respectively) and ultimate failure testing (23.4 ± 3.6 and 20.6 ± 2.3 N/mm; P < .005). The FastFix 360 (86.4 ± 4.8 N) and Stryker AIR (84.4 ± 4.6 N) groups failed at a significantly lower load than the IO-S group ( P < .02) with loss of anchor support. The FiberStich (146.8 ± 23.4 N), TrueSpan (142.0 ± 17.8 N), and IO-ST (139.4 ± 7.3 N) groups failed at significantly higher loads ( P < .02) due to suture tearing. Conclusion: Overall, primary fixation strength of inside-out meniscal repair was significantly lower than all-inside repair in this cadaveric tissue model. Although absolute differences among groups were small, meniscal repairs with higher construct stiffness (IO-ST, FiberStich) demonstrated increased resistance against gap formation and failure load. Clinical Relevance: Knotless single-stitch all-inside meniscal repair with a soft anchor resulted in less gapping, but the overall clinical significance on healing rates remains unclear.
Clinical, biochemical and genetic characteristics of MOGS-CDG: a rare congenital disorder of glycosylation
Shimada, Shino , Ng, Bobby G. , White, Amy , Nickander, Kim K., Turgeon, Coleman , Liedtke, Kristen, Lam, Christina , Font–Montgomery, Esperanza , Peck, Dawn , Uhles, Crescenda L , Haynes, Devon , Wheeler, Patricia G. , Bamshad, Michael J. , Nickerson, Deborah A. , Cushing, Tom, Gates, Ryan , Gomez‐Ospina, Natalia , Scalco, Fernanda B. , Martinez, Noelia Nunez, Sachdev, Rani , Malone, Stephen , Harris, Rebekah V. , Scheffer, Ingrid E. , Rosenzweig, Sergio D. , Adams, David R. , Gahl, William A. , Malicdan, May Christine V. , Raymond, Kimiyo , Wolfe, Lynne A. , Jarvik, Gail P. , White, Amy L , Liedtke, Kristen L, Peck, Dawn S, Harris, Rebekah V , Scheffer, Ingrid E , Malicdan, May Christine V , Raymond, Kimiyo M, Jarvik, Gail P , Ng, Bobby G , Lourenco, Charles , He, Miao , Umaña, Luis Alfredo , Byers, Heather M. , Smith, Lacey A. , Poduri, Annapurna , Freeze, Hudson H.

Mayo Clinic

Journal of Medical Genetics | July 5, 2022 | Volume: 59 | Issue: 11 | Pages: 1104-1115

10.1136/jmedgenet-2021-108177 | PMID 35790351 Get It

Purpose To summarise the clinical, molecular and biochemical phenotype of mannosyl-oligosaccharide glucosidase-related congenital disorders of glycosylation (MOGS-CDG), which presents with variable clinical manifestations, and to analyse which clinical biochemical assay consistently supports diagnosis in individuals with bi-allelic variants in MOGS. Methods Phenotypic characterisation was performed through an international and multicentre collaboration. Genetic testing was done by exome sequencing and targeted arrays. Biochemical assays on serum and urine were performed to delineate the biochemical signature of MOGS-CDG. Results Clinical phenotyping revealed heterogeneity in MOGS-CDG, including neurological, immunological and skeletal phenotypes. Bi-allelic variants in MOGS were identified in 12 individuals from 11 families. The severity in each organ system was variable, without definite genotype correlation. Urine oligosaccharide analysis was consistently abnormal for all affected probands, whereas other biochemical analyses such as serum transferrin analysis was not consistently abnormal. Conclusion The clinical phenotype of MOGS-CDG includes multisystemic involvement with variable severity. Molecular analysis, combined with biochemical testing, is important for diagnosis. In MOGS-CDG, urine oligosaccharide analysis via matrix-assisted laser desorption/ionisation time-of-flight mass spectrometry can be used as a reliable biochemical test for screening and confirmation of disease.
Responsiveness and interpretation of the PROMIS Cancer Function Brief 3D Profile
Smith, Sean R. , Vargo, Mary , Zucker, David S., Shahpar, Samman , Henderson, Maryanne, Jay, Gina , Cheville, Andrea , Cheville, Andrea L , Gerber, Lynn H.

Mayo Clinic

Cancer | July 5, 2022 | Volume: 128 | Issue: 17 | Pages: 3217-3223

10.1002/cncr.34376 | PMID 35788990 Get It

BackgroundMeasuring function with valid and responsive tools in patients with cancer is essential for driving clinical decision‐making and for the end points of clinical trials. Current patient‐reported outcome measurements of function fall short for many reasons. This study evaluates the responsiveness of the Patient‐Reported Outcomes Measurement Information System (PROMIS) Cancer Function Brief 3D Profile, a novel measure of function across multiple domains.MethodsTwo hundred nine participants across five geographically distinct tertiary care centers completed the assessment and pain rating at two outpatient cancer rehabilitation clinic visits. Patients and providers completed a global rating of change measure at the second visit to indicate whether the patient was improving or worsening in function. Multiple response indices and linear models measured whether the measure was responsive to self‐reported and clinician‐rated changes over time. Correlations between changes in function and changes in anchors (pain rating and performance status) were also calculated.ResultsFunction as measured by the PROMIS Cancer Function Brief 3D Profile changed appropriately as both patients and clinicians rated change. Small to moderate effect sizes supported the tool's responsiveness. Function was moderately correlated with pain and more strongly correlated with performance status, and changes in function corresponded with changes in anchor variables. No floor/ceiling effect was found.ConclusionsThe PROMIS Cancer Function Brief 3D Profile is sensitive to changes over time in patients with cancer. The measure may be useful in clinical practice and as an end point in clinical trials.Lay summary We gave patients a questionnaire by which they told their physicians how well they were functioning, including how fatigued they were. This study tested that questionnaire to see whether the scores would change if patients got better or worse.
Prothrombin Complex Concentrate vs Plasma for Post–Cardiopulmonary Bypass Coagulopathy and Bleeding
Schroeder, Darrell R. , Nelson, James A. , Mauermann, William J., Pochettino, Alberto , Montonye, Beth L., Assawakawintip, Chalailak, Nuttall, Gregory A. , Schroeder, Darrell , Smith, Mark M. , Nelson, James A., Welsby, Ian J

Mayo Clinic

JAMA Surgery | June 29, 2022 | Volume: 157 | Issue: 9 | Pages: 757

10.1001/jamasurg.2022.2235 | PMID 35767271 Get It

Evaluation of Sensitivity to Endocrine Therapy Index (SET2,3) for Response to Neoadjuvant Endocrine Therapy and Longer-Term Breast Cancer Patient Outcomes (Alliance Z1031)
Du, Lili, Hoskin, Tanya L. , Anurag, Meenakshi , Cynthia, X. , Bedrosian, Isabelle , Hunt, Kelly K. , Ellis, Matthew J. , Symmans, W. Fraser , Du, Lili , Hoskin, Tanya , Anurag, Meenakshi , Ma, Cynthia , Bedrosian, Isabelle , Hunt, KK , Ellis, Matthew J , Symmans, W Fraser , Suman, Vera J.

Mayo Clinic

Clinical Cancer Research | June 27, 2022 | Volume: 28 | Issue: 15 | Pages: 3287-3295

10.1158/1078-0432.ccr-22-0068 | PMID 35653124 Get It

Abstract Purpose: To evaluate prediction of response and event-free survival (EFS) following neoadjuvant endocrine therapy by SET2,3 index of nonproliferation gene expression related to estrogen and progesterone receptors adjusted for baseline prognosis. Experimental Design: A correlative study was conducted of SET2,3 measured from gene expression profiles of diagnostic tumor (Agilent microarrays) in 379 women with cStage II–III breast cancer from the American College of Surgeons Oncology Group Z1031 neoadjuvant aromatase inhibitor trial SET2,3 was dichotomized using the previously published cutoff. Fisher exact test was used to assess the association between SET2,3 and low proliferation at week 2–4 [Ki67 ≤ 10% or complete cell-cycle arrest (CCCA; Ki67 ≤ 2.7%)] and PEPI-0 rate in cohort B, and the association between SET2,3 and ypStage 0/I in all patients. Cox models were used to assess EFS with respect to SET2,3 excluding cohort B patients who switched to chemotherapy. Results: Patients with high SET2,3 had higher rate of pharmacodynamic response than patients with low SET2,3 (Ki67 ≤ 10% in 88.2% vs. 56.9%, P &lt; 0.0001; CCCA in 50.0% vs. 26.2%, P = 0.0054), but rate of ypStage 0/I (24.0% vs. 20.4%, P = 0.4580) or PEPI = 0 (28.4% vs. 20.6%, P = 0.3419) was not different. Patients with high SET2,3 had longer EFS than patients with low SET2,3 (HR, 0.52, 95% confidence interval: 0.34–0.80; P = 0.0026). Conclusions: This exploratory analysis of Z1031 data demonstrated a higher rate of pharmacodynamic suppression of proliferation and longer EFS in high SET2,3 disease relative to low SET2,3 disease. The ypStage 0/I rate and PEPI = 0 rate were similar with respect to SET2,3.
Procedural learning, declarative learning, and working memory as predictors of learning the use of a memory compensation tool in persons with amnestic mild cognitive impairment
Wit, Liselotte De , Levy, Shellie‐Anne , Amofa, Priscilla , DeFeis, Brittany , O’Shea, Deirdre , Chandler, Melanie , De Wit, Liselotte , Chandler, Melanie J, Kurasz, Andrea M. , Smith, Glenn E.

Mayo Clinic

Neuropsychological Rehabilitation | June 24, 2022 | Volume: 33 | Issue: 7 | Pages: 1278-1303

10.1080/09602011.2022.2089697 | PMID 35749375 Get It

P1115: A MULTICENTER PHASE 1/2 TRIAL OF EO2463, A MICROBIAL-DERIVED PEPTIDE THERAPEUTIC VACCINE, AS MONOTHERAPY AND IN COMBINATION WITH LENALIDOMIDE AND RITUXIMAB, FOR TREATMENT OF PATIENTS WITH INDOLENT NHL
Zinzani, P. L., Ansell, S. M., Bosch, F., Friedberg, Jonathan W. , Marolleau, Jean Pierre, Arcaini, L., Gopal, A. K., Grande, C., Merryman, R., Pinto, A., Smith, S. D., Wallace, D., Fagerberg, J., Magalhaes, J. G., Armand, P., Zinzani, Pier Luigi , Ansell, Stephen M., García‐Sánz, Ramón , Gopal, A., Pinto, A., Villasboas, José C. , Fagerberg, J., Magalhaes, J. Gamelas

Mayo Clinic

HemaSphere | June 23, 2022 | Volume: 6 | Issue: No issue available | Pages: 1005-1006

10.1097/01.hs9.0000847328.48663.29 Get It